Debiopharm
Chemin Messidor 5-7
Case Postale 5911
Lausanne
CH - 1002
Tel: 41-21-321-0111
Fax: 41-21-321-0169
Website: http://www.debiopharm.com/
210 articles about Debiopharm
-
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers
9/21/2023
Debiopharm announced an exclusive option and license agreement with SunRock Biopharma, a Galician company supported by the regional government, Xunta de Galicia, through Xesgalicia, devoted to the development of antibodies against highly invasive tumors with an urgent clinical need in oncology, for the advancement of the development of specifically targeted antibodies.
-
Debiopharm Joins Discussions With International Health Organisations to Fight Anti-Microbial Resistance at the 2023 World AMR Congress
9/6/2023
Debiopharm, a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, announced their participation in the keynote panel and antibiotic development track sessions at the 2023 World AMR conference from September 7th – 8th, 2023.
-
Debiopharm Shares Oncology Program Updates at ASCO 2023 for Novel WEE1 Inhibitor, and First-in-Class CA IX Theranostic Approach
6/1/2023
Debiopharm, a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, announced data releases on two investigational products, namely Debio 0123, and Debio 0228/0328, at the 2023 American Society of Clinical Oncology meeting in Chicago, Illinois.
-
DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
3/22/2023
Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, today announced the first patient dosed of their first-in-human, phase 1/2 study, GaLuCi™.
-
DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
1/12/2023
Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced that the first patient was dosed with Debio 4126, a 3-month extended-release formulation of octreotide, in their open-label, non-randomized, single-arm, multicenter phase 1b study (Debio 4126-102).
-
Debiopharm leads $6M round for YonaLink to Scale Global Growth and Fuel Expansion of Platform Designed to Stream Clinical Trial Data
11/9/2022
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, and YonaLink, a clinical trial software provider, announced having completed an initial funding round, raising $6 million, to scale global growth and expand YonaLink's EHR-to-EDC integration platform.
-
One Drug for One Bug: Debiopharm to Discuss the Potential of Pathogen-Specific Antibiotics at the 2022 World AMR Congress
9/8/2022
Debiopharm, a privately-owned, Swiss-based, biopharmaceutical company committed to the development of novel class antibiotics, revealed its involvement in three panel discussions at the World AMR Congress, taking place in Fort Washington, Maryland, from September 7th – 8th.
-
Series A financing round lays foundation for international growth of digital cancer therapeutics Mika
5/9/2022
Berlin-based digital health company Fosanis, the developer of Mika, Germany's first prescription DTx for all oncological indications, closed a series A funding round of more than 10 million EUR.
-
Debiopharm Announces Oncology Research Advancements At AACR 2022 For Novel Cancer Compounds And Drug Delivery Technologies
4/11/2022
Debiopharm announced data releases on 3 investigational products including Debio 0123, clinical exploratory results for xevinapant, and 2 Multilink™ technology posters at the 2022 Annual American Association for Cancer Research meeting in New Orleans, Louisiana.
-
Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study
12/16/2021
Debiopharm, a Swiss biopharmaceutical company, announced the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123, an oral, potent and highly selective WEE1 inhibitor, as monotherapy in patients with advanced solid tumors.
-
Debiopharm Encourages Breakthrough Cancer Research in Japan Through its Competitive JCA Mauvernay Award
10/4/2021
Debiopharm, a Swiss-based global biopharmaceutical company, announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Shumpei Ishikawa and Translational Research – Dr. Hiromichi Ebi.
-
Biopharma and life sciences companies from across the globe provide updates on their business operations and pipelines.
-
Debiopharm and Ubix Therapeutics Launch Research to Develop a New Anti-Cancer Modality - Antibody Degraducer® Conjugates
6/16/2021
Debiopharm today announced their co-research agreement combining two novel proprietary technologies to specifically target cancer cells.
-
Debiopharm's CD37 Antibody Drug Conjugate Shows Promising Phase II Results for the Treatment of B-Cell Malignancies
6/14/2021
Debiopharm today announced the phase II results assessing naratuximab emtansine (Debio 1562, formerly IMGN529) for the treatment of DLBCL and other B-cell malignancies.
-
Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
3/1/2021
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care
-
Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant
3/1/2021
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care
-
Merck KGaA, Darmstadt, Germany plunked down €188 million (about $226 million) in upfront cash to acquire exclusive global development and commercialization rights to Debiopharm’s oral Inhibitor of Apoptosis Proteins (IAP) antagonist, xevinapant.
-
Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients
2/24/2021
Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates
-
BioSpace Global Roundup, Sept. 24
9/24/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Debiopharm Honored as a 2020 Swiss Biotech Success Story Winner For Outstanding Achievements Over 40 Years
9/22/2020
Debiopharm, ( www.debiopharm.com ), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or individuals within the biotech sector i